Verrica Milestones Unlock Full $27.5 Million Credit Facility
Achievement of predefined revenue, growth and operational milestones increases the facility commitment by $15.0 million. The capital is available to support the YCANTH business and the company’s global Phase 3 common warts program through topline data readout.
Story updates
12:05:00 PM UTC
SquawkNews
Verrica Pharmaceuticals Inc. achieved milestones that increase its credit facility commitment, unlocking the full $27.5M, with $12.5M funded in September. Funds support YCANTH growth and Phase 3 common warts studies, with first topline readout expected in Q1’27.Material DetailsContext by AI Analyst…
Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million —— Capital now available to support continued growth of the YCANTH® business and advancement of the Company’s global Phase 3 common warts program through topline data rea…